Intermediate fixed coronary artery stenosis at the site of ergonovine-provoked spasm as a predictor of long-term major adverse cardiac events of patients with coronary spastic angina

Circ J. 2009 Apr;73(4):699-704. doi: 10.1253/circj.cj-08-0774. Epub 2009 Feb 18.

Abstract

Background: Organic coronary artery stenosis is a significant prognostic factor in patients with coronary spastic angina (CSA), so the present study was focused on assessing the impact of intermediate fixed stenosis at sites of provoked spasm on the long-term outcomes of CSA patients.

Methods and results: CSA patients diagnosed on the basis of ergonovine-provoked spasm were enrolled and the clinical background and long-term prognosis of CSA patients with intermediate fixed stenosis at the site of provoked spasm (with-fixed-stenosis group, n=37) and those without fixed stenosis (without-fixed-stenosis group, n=126) were retrospectively compared. During the follow-up period (average 4.01 years for with-fixed-stenosis, 4.47 years for without-fixed-stenosis), the with-fixed-stenosis group had a significantly lower event-free survival rate, as well as a higher frequency of admission for unstable angina and percutaneous coronary intervention than the without-fixed-stenosis group, whereas the survival rate did not differ significantly between the 2 groups. In the multivariate analysis, intermediate fixed stenosis at the site of provoked spasm was a predictor of long-term major adverse cardiac events (MACE).

Conclusions: Intermediate fixed stenosis at the site of ergonovine-provoked spasm is an independent risk factor for MACE during the long-term period in CSA patients.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Angina Pectoris / mortality*
  • Coronary Stenosis / chemically induced
  • Coronary Stenosis / mortality*
  • Coronary Vessels*
  • Disease-Free Survival
  • Ergonovine / administration & dosage
  • Ergonovine / adverse effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Oxytocics / administration & dosage
  • Oxytocics / adverse effects*
  • Retrospective Studies
  • Spasm / chemically induced
  • Spasm / mortality*
  • Survival Rate

Substances

  • Oxytocics
  • Ergonovine